MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

MDT

85.6

-1.76%↓

118.07

-1.12%↓

VEEV

167.35

-0.11%↓

HQY

84.4

+0.63%↑

NEOG

9.24

-2.01%↓

Kodu・Aktsiate loetelu・Denali Therapeutics Inc

Denali Therapeutics Inc

Avatud

SektorTervishoid

20.72 -4.21

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

20.57

Max

21.58

Põhinäitajad
By Trading Economics
Sissetulek	-1.6M -129M
Töötajad	503
EBITDA	8.9M -125M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+67.3% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-178M 3.1B
Eelmine avamishind	24.93
Eelmine sulgemishind	20.72

Uudiste sentiment

By Acuity

50%

167 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

13.355 / 16.44 Toetus ja vastupanu

Denali Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. apr 2026, 23:14 UTC

Tulu

Battery Maker CATL First-Quarter Net Rose on Strong Demand

15. apr 2026, 23:14 UTC

Tulu

Battery Maker CATL First Quarter Net Rose On Strong Demand

15. apr 2026, 17:13 UTC

Suurimad hinnamuutused turgudel

Tesla Shares Rise on Completion of AI5 Chip Design Process

15. apr 2026, 23:39 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

15. apr 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Gold Rises Amid Hopes for More U.S.-Iran Talks -- Market Talk

15. apr 2026, 22:41 UTC

Tulu

CATL 1Q Net CNY20.74 Vs. Net CNY13.96B >300750.SZ

15. apr 2026, 22:38 UTC

Tulu

CATL 1Q Rev CNY129.13B Vs. CNY84.70B >300750.SZ

15. apr 2026, 22:15 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. apr 2026, 22:15 UTC

Market Talk

J.B. Hunt Flag Fundamental Shift in 1Q -- Market Talk

15. apr 2026, 22:14 UTC

Tulu

Lens Technology Results Weighed by Lower Rev From Smartphone, Computer Business >300433.SZ

15. apr 2026, 22:12 UTC

Tulu

Lens Technology 1Q Oper Income CNY14.14B Vs. CNY17.06B>300433.SZ

15. apr 2026, 22:11 UTC

Tulu

Lens Technology 1Q Loss CNY149.60M Vs. Net CNY428.88M >300433.SZ

15. apr 2026, 22:11 UTC

Tulu

Lens Technology Swings to Loss in 1Q>300433.SZ

15. apr 2026, 22:07 UTC

Tulu

Big Bank Earnings Show Consumers Are on Solid Ground -- Against All Odds -- Barrons.com

15. apr 2026, 21:34 UTC

Omandamised, ülevõtmised, äriostud

Skild AI Acquires Zebra Technologies' Robotics Automation Business

15. apr 2026, 21:29 UTC

Kuumad aktsiad

Stocks to Watch: Bank of America, Live Nation, Snap, Hermès -- WSJ

15. apr 2026, 20:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

15. apr 2026, 20:30 UTC

Tulu

PepsiCo Cuts Prices, Revamps Products. Earnings Will Show if It's Working. -- Barrons.com

15. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

15. apr 2026, 20:06 UTC

Market Talk

Silver Inches Up as Attention Turns to World Deficit -- Market Talk

15. apr 2026, 19:46 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Jamie Dimon Says JPMorgan Stock Isn't Cheap. Why the Bank Is Still Buying Back Billions. -- Barrons.com

15. apr 2026, 19:25 UTC

Market Talk

Automakers' 1Q Earnings Could Give Clues to EV Comeback -- Market Talk

15. apr 2026, 19:00 UTC

Market Talk

U.S. Natural Gas Edges Up Ahead of Storage Data -- Market Talk

15. apr 2026, 18:58 UTC

Market Talk

Uudisväärsed sündmused

Oil Settles Flat As Market Awaits Conflict Developments -- Market Talk

15. apr 2026, 18:11 UTC

Omandamised, ülevõtmised, äriostud

Three Lessons From Amazon's Blockbuster Deal to Buy Globalstar -- Barrons.com

15. apr 2026, 17:45 UTC

Omandamised, ülevõtmised, äriostud

Apple CEO Tim Cook Buys Nike Stock. His Last Purchase Didn't Go So Well. -- Barrons.com

15. apr 2026, 16:58 UTC

Tulu

Bank of America's Wealth Management Profits Rise Amid 'Resilient' U.S. Economy -- Barrons.com

15. apr 2026, 16:52 UTC

Tulu

Snap and Other Companies Blame AI for Layoffs. Is It Just a Convenient Excuse? -- Barrons.com

15. apr 2026, 16:46 UTC

Market Talk

Uudisväärsed sündmused

U.S. Crude Oil Stocks Finally See Drawdowns -- Market Talk

15. apr 2026, 16:37 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Denali Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

67.3% tõus

12 kuu keskmine prognoos

Keskmine 36.27 USD 67.3%

Kõrge 42 USD

Madal 30 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Denali Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Denali Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

13.355 / 16.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

167 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.